Published in Lab Business Week, April 20th, 2008
Excluding net funding of $2.8 million for DelSite Biotechnologies, Inc., the Company's wholly-owned drug delivery subsidiary, the pro forma loss for 2007 was $7.0 million. 2006's net loss, including DelSite net costs of $3.1 million, was $7.6 million, or ($0.70) per basic and diluted share, on Company- wide revenue of $27.4 million.
The decrease in revenue for 2007 was primarily due to a decrease in consumer services revenue, to $11.6 million from $16.6...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.